ClinConnect ClinConnect Logo
Search / Trial NCT04492605

The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults

Launched by TCI CO., LTD. · Jul 27, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two types of probiotics, called TCI378 and TCI507, to see if they can help adults lose weight. Probiotics are friendly bacteria that can benefit our health, and the researchers want to find out if these specific strains can support weight loss in people aged 20 to 65 who have a higher body weight. The trial is currently recruiting participants, so if you're interested and meet the criteria, you could potentially take part.

To be eligible for this study, you need to be an adult between 20 and 65 years old, with a body mass index (BMI) of 24 or higher, which means you may be considered overweight. It's important that you are not pregnant and have no history of certain health issues, like heart disease, major organ disease, or substance abuse. If you join the trial, you can expect to follow a specific plan and report on your weight changes over time. Participating in this study could help researchers learn more about how probiotics might assist with weight loss, which could benefit others in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject.
  • 2. BMI ≥ 24 or male body fat ≥ 25%, female body fat ≥ 30%.
  • 3. Those who are not pregnant and are willing to cooperate with contraception during the trial period.
  • 4. No history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).
  • Exclusion Criteria:
  • 1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental diseases, alcohol or drug abuse, and other major organic diseases (according to medical history).
  • 2. No person who has undergone major surgery or bariatric surgery (according to medical history).
  • 3. Drugs that affect body fat, waist circumference, or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability, have been used at present or within 3 months before participating in the screening Drugs (according to medical history).

About Tci Co., Ltd.

TCI Co., Ltd. is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong focus on improving patient outcomes, TCI Co., Ltd. specializes in designing and managing clinical trials across various therapeutic areas. The company is committed to adhering to the highest standards of regulatory compliance and ethical practices, ensuring the integrity and reliability of its studies. By leveraging cutting-edge technologies and a team of experienced professionals, TCI Co., Ltd. strives to contribute to the development of safe and effective medical treatments, ultimately enhancing the quality of life for patients worldwide.

Locations

Taipei, , Taiwan

Patients applied

0 patients applied

Trial Officials

LIOU JYH-MING

Principal Investigator

National Taiwan University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials